Skip to main content

How effective is Litfulo for alopecia?

Medically reviewed by Kristianne Hannemann, PharmD. Last updated on July 17, 2024.

Official answer

by Drugs.com

About 1 in 4 patients will see hair regrowth covering at least 80% of their scalp within 6 months of taking Litfulo daily. Around 13% of patients taking Litfulo will have at least 90% of scalp coverage after 24 weeks.

At 12 months, about 45% of patients taking Litfulo will have at least 80% scalp coverage, and this number increases to about 61% of patients at 24 months. Around 80% of patients who had at least 80% scalp coverage after 12 months of taking Litfulo daily maintain this response through 24 months.

Litfulo Trial AA-I

In a randomized, double-blind, placebo-controlled trial, Litfulo was studied in patients with alopecia areata. The primary endpoint was Severity of Alopecia Tool (SALT) score 20 or less at week 24. This is a tool researchers use to assess scalp hair loss. Scores range from 0 (no scalp hair loss) to 100 (total scalp hair loss).

After 24 weeks of taking Litfulo 50 mg daily, 23% of patients achieved a SALT score of 20 or less. This means these patients had scalp hair loss of 20% or less (they had at least 80% of scalp hair coverage). This was compared to 1.6% of patients in the placebo group.

How long does it take Litfulo to work?

Litfulo starts working soon after taking a dose. However, it may take at least 4 weeks before you notice the effects of Litfulo. Some people taking Litfulo during clinical studies had 80% of scalp coverage within 4 months.

Lifulo works by blocking immune cells that cause hair loss in people with alopecia areata. This allows hair to regrow, which takes time. Hair on the scalp grows slowly (0.35 mm/day, or 1 cm/month). It is important to take Litfulo daily so it can continue working to allow your hair to grow back.

References

Hoover, E., et. al. (2023). Physiology, Hair. In: StatPearls [Internet]. Accessed July 17, 2024 at https://www.ncbi.nlm.nih.gov/books/NBK499948/

King, B., et. al. (2023). Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial. In: The Lancet. DOI: https://doi.org/10.1016/S0140-6736(23)00222-2

Litfulo [package insert]. (Updated December 2023). Pfizer Laboratories Div Pfizer Inc. Accessed July 17, 2024 at https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6b2f9446-fb23-4741-b73a-5a2f993733c3

Piliang, M., et. al. (2024). Long-Term Efficacy of Ritlecitinib up to Month 24 From the ALLEGRO Phase 2b/3 and Long-Term Phase 3 Clinical Studies in Alopecia Areata. In: Skin, The Journal of Cutaneous Medicine. DOI: https://doi.org/10.25251/skin.8.supp.394

Ramírez-Marín, H. A., et. al. (2022). Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata. In: Drug Design, Development and Therapy. DOI: https://doi.org/10.2147%2FDDDT.S334727

www.litfulo.com. Frequently Asked Questions. Accessed July 17, 2024 at https://www.litfulo.com/faq

Read next

Related medical questions

Drug information

Related support groups